Dan Roden
Faculty Member
Last active: 3/24/2020

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M, Clinical Pharmacogenomics Implementation Consortium (CPIC)
Clin Pharmacol Ther. 2012 92 (1): 112-7

PMID: 22617227 · PMCID: PMC3384438 · DOI:10.1038/clpt.2012.57

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.

MeSH Terms (12)

Drug Prescriptions Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Liver-Specific Organic Anion Transporter 1 Muscular Diseases Organic Anion Transporters Pharmacogenetics Polymorphism, Single Nucleotide Precision Medicine Risk Assessment Risk Factors Simvastatin

Connections (1)

This publication is referenced by other Labnodes entities: